MX368868B - Composiciones farmacéuticas orales de dabigatrán etexilato. - Google Patents
Composiciones farmacéuticas orales de dabigatrán etexilato.Info
- Publication number
- MX368868B MX368868B MX2014010040A MX2014010040A MX368868B MX 368868 B MX368868 B MX 368868B MX 2014010040 A MX2014010040 A MX 2014010040A MX 2014010040 A MX2014010040 A MX 2014010040A MX 368868 B MX368868 B MX 368868B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- dabigatran etexilate
- pharmaceutical compositions
- pharmaceutically acceptable
- oral pharmaceutical
- Prior art date
Links
- 229960000288 dabigatran etexilate Drugs 0.000 title abstract 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical group C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000013150 knee replacement Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000011541 total hip replacement Methods 0.000 abstract 1
- 208000004043 venous thromboembolism Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN461MU2012 | 2012-02-21 | ||
| PCT/EP2013/053426 WO2013124340A1 (en) | 2012-02-21 | 2013-02-21 | Oral pharmaceutical compositions of dabigatran etexilate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010040A MX2014010040A (es) | 2014-11-10 |
| MX368868B true MX368868B (es) | 2019-10-11 |
Family
ID=47739283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010040A MX368868B (es) | 2012-02-21 | 2013-02-21 | Composiciones farmacéuticas orales de dabigatrán etexilato. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11013729B2 (enExample) |
| EP (2) | EP3858337A3 (enExample) |
| JP (1) | JP6215239B2 (enExample) |
| KR (1) | KR102090242B1 (enExample) |
| CN (2) | CN110123774A (enExample) |
| AU (1) | AU2013224146B2 (enExample) |
| BR (1) | BR112014020474B1 (enExample) |
| CA (1) | CA2864423C (enExample) |
| CY (1) | CY1124678T1 (enExample) |
| DK (1) | DK2817000T3 (enExample) |
| ES (1) | ES2895918T3 (enExample) |
| HR (1) | HRP20211606T1 (enExample) |
| HU (1) | HUE056194T2 (enExample) |
| IL (1) | IL234032B (enExample) |
| IN (1) | IN2014DN06734A (enExample) |
| JO (1) | JO3616B1 (enExample) |
| LT (1) | LT2817000T (enExample) |
| MX (1) | MX368868B (enExample) |
| NZ (1) | NZ628301A (enExample) |
| PL (1) | PL2817000T3 (enExample) |
| PT (1) | PT2817000T (enExample) |
| RS (1) | RS62566B1 (enExample) |
| RU (1) | RU2633482C2 (enExample) |
| SI (1) | SI2817000T1 (enExample) |
| SM (1) | SMT202100608T1 (enExample) |
| WO (1) | WO2013124340A1 (enExample) |
| ZA (1) | ZA201405855B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2817000T (pt) | 2012-02-21 | 2021-11-02 | Towa Pharmaceutical Europe S L | Composições farmacêuticas de dabigatrano etexilato |
| CN104224754A (zh) * | 2013-06-21 | 2014-12-24 | 四川海思科制药有限公司 | 一种达比加群酯药物组合物及其制备方法 |
| CN104414995A (zh) * | 2013-09-04 | 2015-03-18 | 天津汉瑞药业有限公司 | 甲磺酸达比加群酯的药用组合物 |
| EP2853260A1 (en) * | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN104784147B (zh) * | 2014-01-20 | 2018-01-23 | 成都苑东生物制药股份有限公司 | 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法 |
| WO2015113324A1 (zh) * | 2014-01-30 | 2015-08-06 | 杭州领业医药科技有限公司 | 达比加群酯及其盐的投药制剂及其制备方法 |
| CN104922092A (zh) * | 2014-03-19 | 2015-09-23 | 陕西天森药物研究开发有限公司 | 一种通过包裹法制备的达比加群酯或其盐和水合物的药物组合 |
| IN2014MU01042A (enExample) | 2014-03-26 | 2015-10-02 | Cadila Healthcare Ltd | |
| CN104095830A (zh) * | 2014-05-22 | 2014-10-15 | 万特制药(海南)有限公司 | 一种甲磺酸盐达比加群酯胶囊的制备方法 |
| CN104825422B (zh) * | 2014-09-29 | 2017-12-12 | 普济生物科技（台州）有限公司 | 含达比加群酯甲磺酸盐的药物组合物及其制备方法 |
| CN105560206A (zh) * | 2014-10-13 | 2016-05-11 | 重庆圣华曦药业股份有限公司 | 一种达比加群酯胶囊的制备 |
| US10675276B2 (en) * | 2014-11-03 | 2020-06-09 | Hangzhou Solipharma Co., Ltd. | Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof |
| WO2016107605A1 (zh) | 2014-12-31 | 2016-07-07 | 昆明积大制药股份有限公司 | 药物组合物及其制备方法 |
| WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
| CN106890148A (zh) * | 2015-12-21 | 2017-06-27 | 青岛黄海制药有限责任公司 | 一种达比加群酯片剂及其制备 |
| WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
| JP2018184375A (ja) * | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法 |
| TR201706848A2 (tr) * | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| WO2019004980A2 (en) * | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |
| TR201722353A2 (tr) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon |
| TR201722323A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
| TR201722630A2 (enExample) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
| CN110339193B (zh) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | 含达比加群酯的药物组合物及其制备方法 |
| WO2020032885A2 (en) | 2018-05-04 | 2020-02-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule-in-capsule compositions of dabigatran etexilate |
| TR201905308A2 (tr) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of dabigatran etexilate |
| CN113577067B (zh) * | 2021-06-03 | 2023-08-15 | 北京福元医药股份有限公司 | 一种甲磺酸达比加群酯药物制剂 |
| CN115006363A (zh) * | 2022-06-23 | 2022-09-06 | 上海信谊万象药业股份有限公司 | 一种牡蛎碳酸钙咀嚼片及其制备方法 |
| WO2024175037A1 (zh) * | 2023-02-21 | 2024-08-29 | 广州玻思韬控释药业有限公司 | 达比加群酯或其药物可接受的盐的微丸 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| JPH04103525A (ja) * | 1990-08-22 | 1992-04-06 | Sanwa Kagaku Kenkyusho Co Ltd | 難水溶性薬物の持続性製剤化方法 |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| AU7375598A (en) | 1997-05-09 | 1998-11-27 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| KR100610131B1 (ko) * | 2000-09-06 | 2006-08-09 | 다나베 세이야꾸 가부시키가이샤 | 경구 투여용 제제 |
| CA2437754C (en) | 2001-02-15 | 2010-05-18 | Tanabe Seiyaku Co., Ltd. | Tablets quickly disintegrated in oral cavity |
| ATE540943T1 (de) * | 2002-03-07 | 2012-01-15 | Boehringer Ingelheim Pharma | 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat |
| DE10209985A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze |
| US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| AU2004289222B2 (en) | 2003-11-04 | 2010-01-21 | Supernus Pharmaceuticals Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
| JP2008501702A (ja) | 2004-06-02 | 2008-01-24 | ファーマサイクリックス，インコーポレイティド | 第ＶＩＩａ因子阻害剤 |
| CN101031570B (zh) | 2004-07-30 | 2012-09-05 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
| JP2008534681A (ja) | 2006-02-09 | 2008-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ジピリダモール持続放出製剤及びそれを調製のための方法 |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| CA2716642C (en) | 2008-03-28 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Method for manufacturing acid pellets |
| RU2010143901A (ru) * | 2008-03-28 | 2012-05-10 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Способ получения композиций дабигатрана для перорального введения |
| RU2529798C2 (ru) | 2008-07-14 | 2014-09-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения лекарственных соединений, содержащих дабигатран |
| EA201201202A1 (ru) * | 2010-03-01 | 2013-04-30 | Рациофарм Гмбх | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана |
| US20130177652A1 (en) * | 2010-07-01 | 2013-07-11 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
| US20120301541A1 (en) | 2011-05-24 | 2012-11-29 | Haronsky Elina | Compressed core for pharmaceutical composition |
| PT2817000T (pt) | 2012-02-21 | 2021-11-02 | Towa Pharmaceutical Europe S L | Composições farmacêuticas de dabigatrano etexilato |
| CN102793699B (zh) | 2012-08-06 | 2014-06-04 | 严轶东 | 一种含有达比加群酯的药用组合物 |
-
2013
- 2013-02-21 PT PT137049748T patent/PT2817000T/pt unknown
- 2013-02-21 RU RU2014138036A patent/RU2633482C2/ru active
- 2013-02-21 HU HUE13704974A patent/HUE056194T2/hu unknown
- 2013-02-21 JO JOP/2013/0057A patent/JO3616B1/ar active
- 2013-02-21 SM SM20210608T patent/SMT202100608T1/it unknown
- 2013-02-21 CN CN201910336600.8A patent/CN110123774A/zh active Pending
- 2013-02-21 WO PCT/EP2013/053426 patent/WO2013124340A1/en not_active Ceased
- 2013-02-21 SI SI201331940T patent/SI2817000T1/sl unknown
- 2013-02-21 EP EP21164447.1A patent/EP3858337A3/en active Pending
- 2013-02-21 PL PL13704974T patent/PL2817000T3/pl unknown
- 2013-02-21 MX MX2014010040A patent/MX368868B/es active IP Right Grant
- 2013-02-21 RS RS20211239A patent/RS62566B1/sr unknown
- 2013-02-21 NZ NZ628301A patent/NZ628301A/en unknown
- 2013-02-21 ES ES13704974T patent/ES2895918T3/es active Active
- 2013-02-21 US US14/379,613 patent/US11013729B2/en active Active
- 2013-02-21 LT LTEPPCT/EP2013/053426T patent/LT2817000T/lt unknown
- 2013-02-21 DK DK13704974.8T patent/DK2817000T3/da active
- 2013-02-21 CN CN201380010066.2A patent/CN104114158A/zh active Pending
- 2013-02-21 AU AU2013224146A patent/AU2013224146B2/en active Active
- 2013-02-21 IN IN6734DEN2014 patent/IN2014DN06734A/en unknown
- 2013-02-21 EP EP13704974.8A patent/EP2817000B1/en active Active
- 2013-02-21 JP JP2014558094A patent/JP6215239B2/ja active Active
- 2013-02-21 CA CA2864423A patent/CA2864423C/en active Active
- 2013-02-21 HR HRP20211606TT patent/HRP20211606T1/hr unknown
- 2013-02-21 BR BR112014020474-8A patent/BR112014020474B1/pt active IP Right Grant
- 2013-02-21 KR KR1020147026330A patent/KR102090242B1/ko active Active
-
2014
- 2014-08-10 IL IL234032A patent/IL234032B/en active IP Right Grant
- 2014-08-11 ZA ZA2014/05855A patent/ZA201405855B/en unknown
-
2021
- 2021-04-27 US US17/241,793 patent/US11752142B2/en active Active
- 2021-10-29 CY CY20211100933T patent/CY1124678T1/el unknown
-
2023
- 2023-07-21 US US18/356,642 patent/US20240139168A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX368868B (es) | Composiciones farmacéuticas orales de dabigatrán etexilato. | |
| PH12022553251A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| IN2014CN00408A (enExample) | ||
| MD4539B1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| CO6640207A2 (es) | Formulaciones de apixaban | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| WO2014064410A3 (en) | Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane | |
| SG10201908582TA (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| IN2014MU01042A (enExample) | ||
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| WO2012113850A3 (en) | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | |
| TN2015000267A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| WO2014141035A3 (en) | Fused heterocyclyl derivatives as nampt inhibitors | |
| MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| MX351180B (es) | Composicion farmaceutica que comprende derivados de piridona. | |
| PH12014501352A1 (en) | Non-enteric pharmaceutical composition comprising crofelemer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: ARLANXEO DEUTSCHLAND GMBH |
|
| FG | Grant or registration |